Semax
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Semax is a synthetic heptapeptide — a chain of seven amino acids — based on the ACTH(4-10) fragment of adrenocorticotropic hormone. Unlike the parent hormone fragment, it is structurally modified for greater stability and is discussed primarily for its effects on the brain rather than on the adrenal system.
It is best known as a nootropic and neuroprotective agent, and has been the subject of research into cognitive performance, focus, and recovery of neural tissue after events such as ischemic stroke. In Russia it is registered and used as a medicine, which sets it apart from many other research peptides.
Outside of Russia, Semax is not approved by major regulators and is generally sold for research use only. Much of the mechanistic evidence to date comes from rodent studies, with human clinical data concentrated in Russian-language literature.
How it works
In preclinical studies, Semax has been reported to increase expression of brain-derived neurotrophic factor (BDNF) and its receptor trkB in the hippocampus — a signaling system closely tied to learning, memory, and neuronal survival. Researchers have suggested this BDNF/trkB modulation may underlie its observed effects on cognition.
Semax has also been reported to influence dopaminergic and serotonergic activity in rodent brain regions, and to affect the transcription of neurotrophins and their receptors after cerebral ischemia. The precise mechanism in humans is not fully established.
Reported benefits
- Enhanced focus, attention, and cognitive performance (studied largely in animals and Russian clinical settings)
- Neuroprotective support following ischemic or hypoxic stress (preclinical and clinical stroke research)
- Increased BDNF expression associated with learning and memory (animal data)
- Reported effects on mood and stress resilience (limited, emerging evidence)
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Because rigorous human safety data outside of Russia is limited, the long-term safety profile of Semax is not well characterized in the broader literature. Reported side effects are generally mild and can include nasal irritation with intranasal use.
As with any research chemical, product purity and concentration vary across the market. Semax is not a substitute for evaluation and treatment by a qualified clinician, and anyone considering it should discuss it with a healthcare professional.
Frequently asked
What is Semax?
A synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) modeled on the ACTH(4-10) fragment of adrenocorticotropic hormone, studied for nootropic and neuroprotective effects, most often via intranasal application.
Is Semax FDA-approved?
No. Semax is registered and used as a medicine in Russia, but it is not approved by the FDA or other major Western regulators, and outside of Russia it is generally sold for research purposes only.
What is Semax studied for?
Preclinical and Russian clinical work has looked at cognition, focus, stress resilience, and recovery after ischemic events such as stroke. Much of the mechanistic evidence comes from animal models.
How is Semax typically administered?
It is most commonly studied and used as an intranasal solution, though injectable forms also exist.
References
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. ↗
- Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. ↗
- Medvedeva EV, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. ↗
Related compounds
Standardized neuropeptide preparation with neurotrophic and neuroprotective properties. Used clinically in 50+ countries for stroke recovery, traumatic brain injury, and dementia treatment.
Enhanced and stabilized version of Semax with superior bioavailability. Crosses blood-brain barrier to enhance BDNF expression and hippocampal neuroplasticity for cognitive enhancement.
A synthetic adamantane derivative (actoprotector) marketed in Russia as Ladasten for asthenia and fatigue. It has mild dopaminergic, anti-fatigue, and stimulant-like actions without the rebound of classic stimulants. A small molecule, not a peptide.